OncoZenge AB (publ) (ONCOZ.ST)
OncoZenge AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Bromma, AB, SE. The stock last traded at $3.38, down 0.59% on the session, giving a market capitalisation of $47.5M. Its beta of 1.30 implies it has historically moved more than the broad market.
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
OncoZenge AB (publ) is most often compared with the following Healthcare names: